Cell/Gene Tx channel feed – Endpoints News

Cell/Gene Tx channel feed

Roche wades deeper into the allogeneic CAR-T field, reserving billions for its next early-stage partner

3 years ago

Not yet in the clinic, Beam’s base-edited, off-the-shelf CAR-T put on hold

3 years ago

After netting $200M, Synthego to break ground on its manufacturing facility

3 years ago

Gilead again backs AlloVir's T cell therapy in $127M direct offering

3 years ago

With AAV alternative and DNA writing tech, a new hub-and-spoke startup wants to ‘democratize’ gene therapies

3 years ago

Astellas gathers scattered cell and gene therapy, BD units in new $70M South San Francisco hub

3 years ago

Small UK biotech touts long-term data for hemophilia B gene therapy as it attempts a comeback

3 years ago

Vertex taps Verve for gene editing pact — buying a chunk of shares — as Sek Kathiresan steers base editing into clinic

3 years ago

Gene therapy for ovarian cancer fails PhIII study — sinking biotech's shares

3 years ago

San Francisco cell therapy player lays off 94 staffers as it awaits data on lead candidate

3 years ago

Following Luxturna and slate of eye disease approvals, Roche adds another ophthalmology partner for AAV gene therapies

3 years ago

Gene editing for heart disease: Verve kicks off landmark base editing trial

3 years ago

Vertex nabs ViaCyte's rival diabetes stem cell treatment, acquiring the biotech for $320M in cash

3 years ago

Adverum lays off 38% of staff as it enters new trial for ocular gene therapy after last year's safety woes

3 years ago

Legend scraps trial of its follow-up autologous CAR-T weeks after clinical hold was lifted

3 years ago

Heart inflammation emerges in a Sarepta Duchenne patient, clouding an otherwise positive readout

3 years ago

FDA lifts hold on Vertex's diabetes stem cell therapy after just two months under the microscope

3 years ago

Scoop: A small gene therapy biotech, flush with ex-Sarepta and bluebird leaders, guts CMC

3 years ago

As court case looms, Bristol Myers touts label expansion for Breyanzi

3 years ago

Capricor hits primary endpoint in Duchenne extension study, readying its FDA pitch

3 years ago

No stranger to gene therapy woes, Astellas runs into another safety-related clinical hold

3 years ago

Intellia's CRISPR program that edits genes directly in patients shows durability in ATTR amyloidosis

3 years ago

Scoop: Little-known OrbiMed-backed biotech closes $160M round to start gene therapy trial

3 years ago

In troubled Huntington’s space, uniQure’s gene therapy shows early promise

3 years ago

First page Previous page 27 28 293031 32 33 Next page Last page